Liver injury due to prescription and non-prescription medication is medical, scientific, and public health problem of increasing frequency and importance in United States. Drug-induced liver injury (DILI) is the most common reason the Food and Drug Administration (FDA) would choose not to approve a new drug or withdraw a drug from the market. However, drug-induced liver injuries are often under-reported and difficult to detect/diagnose. This study seeks to learn more about these drug-induced liver injuries and develop better ways to detect, define, and study drug-induced liver injuries. The study will be looking at new cases of drug-induced liver injury, as well as gathering data on previous drug-induced liver injury (up to January 1, 1994).
About two in five people who are undergoing a kidney biopsy have diabetes. Diabetes is a common finding in people with kidney disease, but little is known about the specific ways in which diabetes affects kidney function. The purpose of this study is to gather two groups of patients with diabetes who undergo a kidney biopsy in order to create a source of information with genetic, blood, and urine samples available, by which researchers can study how diabetes affects kidney function.
We have created this registry to provide an opportunity to study diagnostic capabilities, administration protocols and long-term effects of contrast-enhanced ultrasound (CEUS) of any organ.
We are collecting data on children living with chronic kidney disease, including children on dialysis or with a kidney transplant, to learn more about what happens over time. The data collected will be used for research projects.
Current dialysis vascular access patient education materials can be overwhelming, not written in plain language, and not have enough realistic information about the steps involved in getting a dialysis vascular access before starting hemodialysis. This study is being done to create and test a dialysis vascular access educational video for patients. Participants would take part in a one-time interview about their thoughts on dialysis vascular access education and their ideas for a vascular access video.
The purpose of this IRB approved Humanitarian Use of a device is to allow patients to be treated with LDL-Apheresis, using the LIPOSORBER® LA-15 system. This device is approved for adult and pediatric patients with Focal Segmental Glomeruloslerosis as a Humanitarian Use Device. Its effectiveness has not been demonstrated.
We are surveying individuals with sickle cell disease (SCD) and/or parents of a child with SCD to get a sense of the types of treatment they would choose based on the harms and benefits of those treatment options. The proposed study will be designed to meet the following objectives: 1) Elicit individual respondent's maximum acceptable risk (MAR) for treatment benefits 2) Elicit individual respondent's minimum 3) Characterize heterogeneity in MARs and MABs among respondents
This study will collect information about children who have rare types of lung disease to help us understand how better to diagnose and treat these patients. Information will be collected from participants' doctors about how different aspects of their disease and treatment. This will be compared to information from other such patients from other hospitals around the United States. By gathering information on many such patients, we hope to develop best practices for such patients. These may lead to new research studies, which we can invite participants in this study to consider as well.
To test the effect of automated RBC exchange transfusion and standard of care compared with standard of care on the number of episodes of clinical worsening of sickle cell disease (SCD)requiring acute health care encounters (non-elective infusion center/ER/Hospital visits) or resulting in death over 12 months in high risk adult SCD patients.
The purpose of this research study is to evaluate the effects of HM15211 in people with NASH. This study will also evaluate study drug levels in your body and the time it takes your body to eliminate the drug (pharmacokinetics or PK) and what the study drug does to the body (pharmacodynamics or PD).